Skip to main content
main-content
Top

05-06-2022 | EULAR 2022 | Conference coverage | News

Deucravacitinib warrants further investigation for SLE

Author: Claire Barnard

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: The phase 2 PAISLEY study, presented at the EULAR 2022 Congress in Copenhagen, Denmark, suggests that the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib may be a promising novel therapeutic option for systemic lupus erythematosus (SLE).

This agent “binds to the regulatory domain of TYK2, locking the enzyme in the inactive state, differentiating itself therefore from JAK [Janus kinase] inhibitors, which bind to the ATP active site,” Eric Morand (Monash University, Melbourne, Victoria, Australia) told the audience.

He explained that TYK2 is involved in signaling via the type 1 interferon and interleukin (IL)-12/23 pathways, which represent “an attractive pair of therapeutic targets for lupus,” but deucravacitinib “does not inhibit cytokines involved in metabolic or hematopoietic pathways.”

In the PAISLEY study, 363 patients with active SLE – most of whom were on multiple background therapies including antimalarials (86.8%), corticosteroids (80.4%), and immunosuppressants (51.8%) – were randomly assigned to receive one of three doses of deucravacitinib or placebo. Corticosteroid tapering was required from week 8–20, with optional further tapering from week 32–40.

At week 32, the primary endpoint of SRI(4) response rate was higher among participants given deucravacitinib 3 mg twice daily, 6 mg twice daily, or 12 mg once daily than in their counterparts given placebo, at 58.2%, 49.5%, and 44.9% versus 34.4%, respectively. These differences reached statistical significance with the two lower deucravacitinib doses versus placebo.

In addition, SRI(4), BICLA, and LLDAS response rates were evaluated at week 48, with “results favoring deucravacitinib at all doses compared to placebo,” said Morand. The proportion of patients achieving at least a 50% improvement in Cutaneous Lupus Area and Severity Index score at this timepoint was also significantly greater with deucravacitinib versus placebo.

In response to a question from the audience about whether the TYK2 inhibitor had any benefits for lupus manifestations outside of the skin and joints, the presenter said that analyses of other endpoints are ongoing, but data are not yet available.

Turning to safety, Morand reported that deucravacitinib was well tolerated, with a safety profile consistent with that seen previously in psoriatic arthritis and psoriasis trials, despite patients in PAISLEY having “a significant burden of standard-of-care therapy including immunosuppression and steroids.” During 48 weeks of follow-up, there were no deaths, thrombotic events, or major adverse cardiovascular events.

He said that there was “no signal” for increased rates of serious infections, herpes zoster, or COVID-19 with deucravacitinib treatment, but there were higher rates of urinary tract infections in the TYK inhibitor versus placebo arms (6.5–11.0 vs 3.3%), as well as a signal for skin-related adverse events (16.5–34.4 vs 13.3%).

“There was no evidence of laboratory abnormalities that are seen in some patients treated with JAK inhibitors,” noted Morand.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

EULAR 2022; Copenhagen, Denmark: 1–4 June
Ann Rheum Dis 2022; 81: 209

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?